Supriya Lifescience shares jumped over 16% after the company posted a strong Q4FY26 performance, with PAT rising 47% YoY and revenue surging 50%. Robust demand across therapeutic segments, improved capacity utilisation, and traction in regulated markets supported growth. The stock remains in an uptrend despite overbought technical indicators.
Earnings Economic Times May 29, 2026